New IVIG therapy V-IMMUNE tested in phase III trial for immune deficiency
NCT ID NCT06954441
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This phase III trial tests V-IMMUNE, an intravenous immunoglobulin (IVIG) product, in about 50 people with primary immunodeficiency (PID). Participants, aged 2 and older, will switch from their current IVIG to V-IMMUNE every three weeks for a year. The study aims to see if V-IMMUNE prevents serious bacterial infections and is safe, with a focus on infusion-related side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
V-IMMUNE (intravenous immunoglobulin, IVIG)
What this could lead to
If successful, this could provide a safe and effective immunoglobulin replacement option for people with primary immunodeficiency, helping prevent serious infections.
What could go wrong
This is a small, non-randomized trial using historical controls, so results may not be definitive. Infusion-related side effects and thromboembolic risks are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY IMMUNODEFICIENCIES (PID) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
IMIP Centro de Pesquisa
RECRUITINGRecife, Pernanbuco, 50070-902, Brazil
Contact Phone: •••-•••-•••• Email: •••••@•••••